Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Down 6.1 %

Shares of AKTX stock opened at $2.30 on Friday. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $4.40. The firm’s 50 day moving average price is $2.87 and its two-hundred day moving average price is $2.83.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.